Trial Outcomes & Findings for Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer (NCT NCT00195091)
NCT ID: NCT00195091
Last Updated: 2025-05-16
Results Overview
Recruitment status
TERMINATED
Study phase
PHASE2
Target enrollment
16 participants
Primary outcome timeframe
duration of study
Results posted on
2025-05-16
Participant Flow
This study is a transfer study from Weill Cornell to MSKCC. Participants were consented at Weill Cornell and transferred to MSKCC.
Participant milestones
| Measure |
Tetrathiomolybdate (TM)
Tetrathiomolybdate: Induction with Tetrathiomolybdate (TM)
When target Cp window is reached, then the maintenance phase begins.
|
|---|---|
|
Overall Study
STARTED
|
16
|
|
Overall Study
COMPLETED
|
0
|
|
Overall Study
NOT COMPLETED
|
16
|
Reasons for withdrawal
| Measure |
Tetrathiomolybdate (TM)
Tetrathiomolybdate: Induction with Tetrathiomolybdate (TM)
When target Cp window is reached, then the maintenance phase begins.
|
|---|---|
|
Overall Study
Study terminated and PI has left MSKCC
|
16
|
Baseline Characteristics
Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer
Baseline characteristics by cohort
| Measure |
Tetrathiomolybdate (TM)
n=16 Participants
Tetrathiomolybdate: Induction with Tetrathiomolybdate (TM)
When target Cp window is reached, then the maintenance phase begins.
|
|---|---|
|
Age, Continuous
|
64 years
n=5 Participants
|
|
Sex: Female, Male
Female
|
16 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
11 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
5 Participants
n=5 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Asian
|
1 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
White
|
14 Participants
n=5 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
16 Participants
n=5 Participants
|
PRIMARY outcome
Timeframe: duration of studyPopulation: N/A - data were not collected
Outcome measures
Outcome data not reported
Adverse Events
Tetrathiomolybdate (TM)
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Dr. Tiffany Traina MD
Memorial Sloan Kettering Cancer Center
Phone: 646-888-4558
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place